New strategies in the molecular targeting of glioblastoma: How do you hit a moving target?

Clinical Cancer Research

Volumn 17, Issue 1, 2011, Pages 6-11

  Cloughesy, Timothy F ^a   Mischel, Paul S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RETINOBLASTOMA BINDING PROTEIN 2; RETINOBLASTOMA PROTEIN; S6 KINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURGERY; CELL METABOLISM; CHRONIC MYELOID LEUKEMIA; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC VARIABILITY; GENOMICS; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MITOSIS INHIBITION; MOLECULAR DIAGNOSIS; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; MUTATION RATE; NEGATIVE FEEDBACK; PERSONALIZED MEDICINE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 78751556796     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2268     Document Type: Article

References (22)

1. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
2. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008;27:5527-41.
3. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
4. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009;69:565-72.
5. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88.
6. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90.
7. Gazdar AF. Activating and resistance mutations of EGFR in nonsmallcell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28[Suppl 1]:S24-31.
8. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007;13:1089-97.
9. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
10. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-56.
11. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
12. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
13. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002;1:269-77.
14. Cheng CK, Fan QW, Weiss WA. PI3K signaling in glioma-animal models and therapeutic challenges. Brain Pathol 2009;19:112-20.
15. Ding H, Shannon P, Lau N, Wu X, Roncari L, Baldwin RL, et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res 2003;63:1106-13.
16. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001;2:120-9.
17. Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, Gage FH, et al. Development of a novel mouse glioma model using lentiviral vectors. Nat Med 2009;15:110-6.
18. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 2001;61:6674-8.
19. Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 2003;63:1589-95.
20. Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 2002;1:157-68.
21. Xiao A, Yin C, Yang C, Di Cristofano A, Pandolfi PP, Van Dyke T. Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res 2005;65:5172-80.
22. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005;8:119-30.